CINC
NASDAQCinCor Pharma Inc.
CinCor Pharma Inc. (CINC) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for CINC in the last 30 days. The most recent was published Oct 30, 2024.
Latest news
25 items- PRAxonis Therapeutics Announces $115 Million Series A Financing-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent
- PRvenBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo
- PRImpel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business UpdateTrudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of
- PR5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough ScienceSAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade. REZZAYO was developed by Cidara Therapeutics, Inc. (NASDAQ:CDTX), a company seeded and then supported by 5AM Ventures through its Series A and Series B rounds. 5AM's Scott Rocklage served as chair of the board of directors from the company's inception in 2012 through 2019. "Su
- 13D/GSEC Form SC 13D/A filed by CinCor Pharma Inc. (Amendment)SC 13D/A - CinCor Pharma, Inc. (0001868734) (Subject)
- 13D/GSEC Form SC 13D/A filed by CinCor Pharma Inc. (Amendment)SC 13D/A - CinCor Pharma, Inc. (0001868734) (Subject)
- 13D/GSEC Form SC 13D/A filed by CinCor Pharma Inc. (Amendment)SC 13D/A - CinCor Pharma, Inc. (0001868734) (Subject)
- INSIDERSEC Form 4 filed by 5am Partners Vi, Llc4 - CinCor Pharma, Inc. (0001868734) (Issuer)
- 13D/GSEC Form SC 13D/A filed by CinCor Pharma Inc. (Amendment)SC 13D/A - CinCor Pharma, Inc. (0001868734) (Subject)
- INSIDERSEC Form 4: Healy James returned 19,608 shares to the company and sold $85,920 worth of shares (6,000 units at $14.32), closing all direct ownership in the company4 - CinCor Pharma, Inc. (0001868734) (Issuer)
- INSIDERSEC Form 4: Freeman Mason returned 40,000 shares to the company and sold $91 worth of shares (6 units at $15.21), closing all direct ownership in the company to satisfy withholding tax4 - CinCor Pharma, Inc. (0001868734) (Issuer)
- INSIDERSEC Form 4 filed by Allison David D.4 - CinCor Pharma, Inc. (0001868734) (Issuer)
- INSIDERSEC Form 4 filed by Ignelzi Troy A.4 - CinCor Pharma, Inc. (0001868734) (Issuer)
- INSIDERSEC Form 4: Kalb Michael Wayne returned 202,437 shares to the company, closing all direct ownership in the company4 - CinCor Pharma, Inc. (0001868734) (Issuer)
- INSIDERSEC Form 4 filed by Lee June4 - CinCor Pharma, Inc. (0001868734) (Issuer)
- INSIDERSEC Form 4: Pearce Catherine returned 15,000 shares to the company, closing all direct ownership in the company (tax withholding)4 - CinCor Pharma, Inc. (0001868734) (Issuer)
- INSIDERSEC Form 4 filed by Thero John F4 - CinCor Pharma, Inc. (0001868734) (Issuer)
- INSIDERSEC Form 4: De Garidel Marc returned 200,000 shares to the company, closing all direct ownership in the company to cover taxes4 - CinCor Pharma, Inc. (0001868734) (Issuer)
- SECCinCor Pharma Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits8-K - CinCor Pharma, Inc. (0001868734) (Filer)
- SECSEC Form 25-NSE filed by CinCor Pharma Inc.25-NSE - CinCor Pharma, Inc. (0001868734) (Subject)
- SECSEC Form SC 14D9/A filed by CinCor Pharma Inc. (Amendment)SC 14D9/A - CinCor Pharma, Inc. (0001868734) (Subject)
- SECSEC Form SC TO-T/A filed by CinCor Pharma Inc. (Amendment)SC TO-T/A - CinCor Pharma, Inc. (0001868734) (Subject)
- SECSEC Form SC 14D9/A filed by CinCor Pharma Inc. (Amendment)SC 14D9/A - CinCor Pharma, Inc. (0001868734) (Subject)
- SECSEC Form SC TO-T/A filed by CinCor Pharma Inc. (Amendment)SC TO-T/A - CinCor Pharma, Inc. (0001868734) (Subject)
- SECCinCor Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - CinCor Pharma, Inc. (0001868734) (Filer)
CINC FAQ
8 questionsWhat does CinCor Pharma Inc. do?
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.What is the latest news on CINC?
Quantisnow has not tracked any new filings, ratings or press releases for CINC in the last 30 days. The most recent wire item was published on October 30, 2024.Where does CINC stock trade?
CinCor Pharma Inc. (CINC) is listed on NASDAQ.What sector and industry is CINC in?
CinCor Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did CinCor Pharma Inc. go public?
CinCor Pharma Inc. (CINC) completed its IPO in 2022.What are analysts saying about CINC?
Across the last 8 analyst actions on CinCor Pharma Inc., there were 0 upgrades and 2 downgrades. The most recent action was from Barclays: Overweight with a $22.00 price target on 2022-12-07. Recent price targets range from $22.00 to $73.00.What companies are similar to CINC?
Notable peers in the same industry include MRK (Merck & Company Inc.), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare CINC side-by-side with any of them on Quantisnow.How can I track CINC on Quantisnow?
Quantisnow aggregates CinCor Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CINC to receive live email and push alerts on every new disclosure.